(Q68715270)

English

Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experime

scientific article published on 01 January 1990

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

1 reference

based on heuristic

inferred from title

colon carcinoma

1 reference

based on heuristic

inferred from title

author name string

M Rodolfo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

C Salvi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

C Bassi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

G Parmiani

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

publication date

1 January 1990

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

28-36

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

https://scigraph.springernature.com/pub.10.1007/bf01742492

0 references

In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Establishment of mouse colonic carcinoma cell lines with different metastatic properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of cancer using interleukin 2: current status and future prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local and systemic effects during interleukin-2 therapy of mouse mammary tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accurate identification of experimental pulmonary metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth inhibition of murine colonic adenocarcinoma by tumor immune but not by IL-2-activated or alloactivated lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/2306753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01742492

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2306753%20AND%20SRC:MED&resulttype=core&format=json

26 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q68715270&oldid=2183736295"